Literature DB >> 32113617

Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.

Elisabeth Fenwick1, Lotte Steuten2, Saskia Knies3, Salah Ghabri4, Anirban Basu5, James F Murray6, Hendrik Erik Koffijberg7, Mark Strong8, Gillian D Sanders Schmidler9, Claire Rothery10.   

Abstract

Healthcare resource allocation decisions made under conditions of uncertainty may turn out to be suboptimal. In a resource constrained system in which there is a fixed budget, these suboptimal decisions will result in health loss. Consequently, there may be value in reducing uncertainty, through the collection of new evidence, to make better resource allocation decisions. This value can be quantified using a value of information (VOI) analysis. This report, from the ISPOR VOI Task Force, introduces VOI analysis, defines key concepts and terminology, and outlines the role of VOI for supporting decision making, including the steps involved in undertaking and interpreting VOI analyses. The report is specifically aimed at those tasked with making decisions about the adoption of healthcare or the funding of healthcare research. The report provides a number of recommendations for good practice when planning, undertaking, or reviewing the results of VOI analyses.
Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Keywords:  decision making; expected net benefit of sampling; expected value of information; expected value of perfect information; value of information; value of research

Mesh:

Year:  2020        PMID: 32113617     DOI: 10.1016/j.jval.2020.01.001

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  28 in total

1.  A critical assessment framework to identify, quantify and interpret the sources of uncertainty in cost-effectiveness analyses.

Authors:  Gergő Merész; Veronika Dóczy; Áron Hölgyesi; Gergely Németh
Journal:  BMC Health Serv Res       Date:  2022-06-25       Impact factor: 2.908

2.  A guide to value of information methods for prioritising research in health impact modelling.

Authors:  Christopher Jackson; Robert Johnson; Audrey de Nazelle; Rahul Goel; Thiago Hérick de Sá; Marko Tainio; James Woodcock
Journal:  Epidemiol Methods       Date:  2021-11-15

3.  Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study.

Authors:  Christopher J Cadham; Pianpian Cao; Jinani Jayasekera; Kathryn L Taylor; David T Levy; Jihyoun Jeon; Elena B Elkin; Kristie L Foley; Anne Joseph; Chung Yin Kong; Jennifer A Minnix; Nancy A Rigotti; Benjamin A Toll; Steven B Zeliadt; Rafael Meza; Jeanne Mandelblatt
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 11.816

4.  Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research.

Authors:  Natalia Kunst; Natasha K Stout; Grace O'Brien; Kurt D Christensen; Pamela M McMahon; Ann Chen Wu; Lisa R Diller; Jennifer M Yeh
Journal:  J Natl Cancer Inst       Date:  2022-05-09       Impact factor: 11.816

5.  The Application and Implications of Novel Deterministic Sensitivity Analysis Methods.

Authors:  Rick A Vreman; Joost W Geenen; Saskia Knies; Aukje K Mantel-Teeuwisse; Hubert G M Leufkens; Wim G Goettsch
Journal:  Pharmacoeconomics       Date:  2020-12-14       Impact factor: 4.981

6.  Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases").

Authors:  Sabine E Grimm; Xavier Pouwels; Bram L T Ramaekers; Ben Wijnen; Saskia Knies; Janneke Grutters; Manuela A Joore
Journal:  Orphanet J Rare Dis       Date:  2021-02-01       Impact factor: 4.123

7.  Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers.

Authors:  Gabrielle Jongeneel; Marjolein J E Greuter; Natalia Kunst; Felice N van Erning; Miriam Koopman; Jan P Medema; Louis Vermeulen; Jan N M Ijzermans; Geraldine R Vink; Cornelis J A Punt; Veerle M H Coupé
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-06-23       Impact factor: 4.090

8.  Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.

Authors:  Jonathan Salcedo; Jenniffer Bulovic; Colin M Young
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

9.  Cost-effectiveness of procedure-less intragastric balloon therapy as substitute or complement to bariatric surgery.

Authors:  Shweta Mital; Hai V Nguyen
Journal:  PLoS One       Date:  2021-07-28       Impact factor: 3.240

10.  Adapting interventions to new contexts-the ADAPT guidance.

Authors:  Graham Moore; Mhairi Campbell; Lauren Copeland; Peter Craig; Ani Movsisyan; Pat Hoddinott; Hannah Littlecott; Alicia O'Cathain; Lisa Pfadenhauer; Eva Rehfuess; Jeremy Segrott; Penelope Hawe; Frank Kee; Danielle Couturiaux; Britt Hallingberg; Rhiannon Evans
Journal:  BMJ       Date:  2021-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.